Comparative Pharmacology
Head-to-head clinical analysis: TZ 3 versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TZ 3 versus WILPO.
TZ-3 vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
100 mg orally twice daily
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown